SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
PHARNEXT Has Completed Patient Recruitment for Its Phase II Clinical Trial of PXT3003 (the Company's First Pleodrug™) in Charcot-Marie-Tooth Disease